

La radioterapia stereotassica in 5 frazioni in pazienti con carcinoma prostatico a rischio basso e intermedio.

Ciro Franzese, Elisa Villa, Cristina Iftode, Angelo Tozzi, Elena Clerici, Tiziana Comito, Anna Maria Ascolese, Fiorenza De Rose, Sara Pentimalli, Pierina Navarria, Marta Scorsetti

U.O. Radioterapia e radiochirurgia, Humanitas Clinical and Research Center, Rozzano (Mi)



Background

- Recent innovations in EBRT, which combine IGRT and IMRT, allow for delivery of an increased dose to the target while limiting toxicity to normal tissues.
- Several studies of RT in prostate cancer suggest that prostate tumours may have a low alpha/beta.

(Brenner et al., 2002; Dasu et al., 2007)

• The linear/quadratic model suggests that SBRT delivered in few fractions of focused high doses should improve the therapeutic ratio in radiotherapy for prostate cancer.

Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study

Filippo Alongi^{1,4*}, Luca Cozzi², Stefano Arcangeli¹, Cristina Iftode¹, Tiziana Comito¹, Elisa Villa¹, Francesca Lobefa Pierina Navarria¹, Giacomo Reggiori¹, Pietro Mancosu¹, Elena Clerici¹, Antonella Fogliata², Stefano Tomatis¹, Gianluigi Taverna³, Pierpaolo Graziotti³ and Marta Scorsetti¹



Radiation Oncology 2013, 8:171

Methods and Materials


N. of patients	72
Recruitment	Feb 2012-Dic 2013
Median Age [year]	70 [48, 80]
Mean Gleason Score (composite)	6.3±0.5 (range: 6-7)
Initial PSA [ng/mL]	Mean: 6.95 ±3.0 Range: 0.5-16
NCCN Low Risk Class	47 (65%)
NCCN Intermediate Risk Class	25 (35%)

The schedule was 35 Gy in 5 fractions, delivered on alternate days, by means *Rapid Arc* technique with *Flattening Filter Free* (FFF) beams.


•

Results

Follow-up [months]	Mean: 14.5±6.9
	Range: 6-23
	Median: 15
Nadir PSA [ng/mL]	Mean: 1.29±1.23
	Range: 0.02-7.33
Last PSA [ng/mL]	Mean: 1.41±1.36
	Range: 0.02-7.33




Results



Conclusions

- SBRT with RapidArc and FFF beams for prostate cancer in 5 fractions is a feasable and fast approach.
- •The treatment is very well tolerated in acute and early late settings.
- Longer follow-up is needed for assessment of definitive toxicity data and outcome.



Thank you.